Trial Profile
A phase Ib study of BL-8040 in combination with Atezolizumab in patients with gastric cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2017
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Motixafortide (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- Sponsors Genentech
- 06 Jun 2017 New trial record
- 01 Jun 2017 According to a BioLineRx media release, Genentech has filed regulatory submissions required to commence this trial and the company expects to initiate this trial in the second half of 2017 after receipt of regulatory approval.